REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations

被引：0
|
作者：
Yu, Helena Alexandra
Besse, Benjamin
Nishio, Makoto
Cheng, Ying
Wei, Li
Wacheck, Volker
Heymach, John
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[4] Jilin Canc Hosp, Changchun, Peoples R China
[5] Taiho Oncol Inc, Princeton, NJ USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8671
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
    Woo, Hyun Sun
    Ahn, Hee Kyung
    Lee, Ha Yeon
    Park, Inkeun
    Kim, Young Saing
    Hong, Junshik
    Sym, Sun Jin
    Park, Jinny
    Lee, Jae Hoon
    Shin, Dong Bok
    Cho, Eun Kyung
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1311 - 1315
  • [42] Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis
    Girard, N.
    Park, K.
    Viteri, S.
    Schioppa, C. A.
    Diels, J.
    Oguz, M.
    Rodrigues, B. H.
    Rahhali, N.
    Sermon, J.
    Ghilotti, F.
    Li, T.
    Knoblauch, R. E.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S38 - S38
  • [43] Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab
    Jatkoe, Timothy
    Wang, Songbai
    Odegaard, Justin I.
    Roth, Anne Marie Velasco
    Osgood, Drew
    Martinez, Gabriela
    Lucas, Paul
    Curtin, Joshua C.
    Karkera, Jayaprakash
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (11): : 1181 - 1188
  • [44] A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations
    Imai, Hisao
    Kaira, Kyoichi
    Suzuki, Kensuke
    Anzai, Masaki
    Tsuda, Takeshi
    Ishizuka, Tamotsu
    Kuwako, Tomohito
    Naruse, Ichiro
    Nemoto, Kenji
    Uchino, Junji
    Morozumi, Nobutoshi
    Ishihara, Shinichi
    Minato, Koichi
    Hisada, Takeshi
    LUNG CANCER, 2018, 126 : 41 - 47
  • [45] Multicenter prospective study of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations
    Cardenal, Felipe
    Moran, Teresa
    Queralt, Cristina
    Porta, Ruth
    Camps, Carlos
    Majem, Margarita
    Lopez-Vivanco, Guillermo
    Isla, Dolores
    Provencio, Mariano
    Sanchez, Jose Javier
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S324 - S325
  • [46] Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison
    Ou, Sai -Hong Ignatius
    Prawitz, Thibaud
    Lin, Huamao M.
    Hong, Jin-liern
    Tan, Min
    Proskorovsky, Irina
    Hernandez, Luis
    Jin, Shu
    Zhang, Pingkuan
    Lin, Jianchang
    Patel, Jyoti
    Nguyen, Danny
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2024, 25 (03) : e145 - e152.e3
  • [47] Phase I/II study of osimertinib in EGFR exon 20 insertion mutations in non-small cell lung cancer patients: AEX20.
    Ichihara, Eiki
    Yasuda, Hiroyuki
    Takashima, Yuta
    Zenke, Yoshitaka
    Takeuchi, Shinji
    Morise, Masahiro
    Hotta, Katsuyuki
    Sato, Mineyoshi
    Matsumoto, Shingo
    Tanimoto, Azusa
    Matsuzawa, Reiko
    Kiura, Katsuyuki
    Terai, Hideki
    Ikemura, Shinnosuke
    Goto, Koichi
    Soejima, Kenzo
    CANCER RESEARCH, 2021, 81 (13)
  • [48] THE EFFECTS OF EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR INHIBITORS ON THE IMMUNE SYSTEM IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Meniawy, Tarek
    Lake, Richard
    Nowak, Anna K.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S374 - S374
  • [49] Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
    Yang, J. C-H.
    Ramalingam, S. S.
    Kim, T. M.
    Kim, S-W.
    Riely, G. J.
    Mekhail, T.
    Nguyen, D.
    Campelo, M. R. Garcia
    Felip, E.
    Bazhenova, L.
    Jin, S.
    Griffin, C.
    Bunn, V.
    Lin, J.
    Churchill, E. N.
    Mehta, M.
    Janne, P. A.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S975 - S975
  • [50] Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy
    Aydiner, Adnan
    Sari, Murat
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345